Excision BioTherapeutics Appoints Biotechnology Industry Research & Development Veteran, William Kennedy, M.D., as Senior Vice President, Clinical Development

SAN FRANCISCO, April 01, 2021 (GLOBE NEWSWIRE) — Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry research and development veteran, William Kennedy, M.D., as Senior Vice President, Clinical, effective Thursday, April 1. “Dr. Kennedy’s extensive experience in clinical development is […]